NovaBay Pharmaceuticals to Present at Two Investment Conferences in September
September 03 2019 - 6:50AM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a
biopharmaceutical company focusing on commercializing Avenova® for
the domestic eye care market, announces that management will
present at two upcoming investment conferences:
- RHK Capital 4th Annual Disruptive Growth Conference on
Thursday, September 5 at 11:00 a.m. Eastern time. The conference is
being hosted by Reed Smith LLP in New York City;
- Ladenburg Thalmann 2019 Healthcare Conference on
Tuesday, September 24 at 1:30 p.m. Eastern time. The conference is
being held at the Sofitel New York Hotel.
“We are eager to share the early success of our new
commercialization strategy for Avenova that is aimed at increasing
product accessibility, enhancing the patient experience, and
maintaining product affordability,” said Justin Hall, NovaBay CEO.
“We have improved the efficiency of both our prescription sales and
direct sales channels, and just recently launched Avenova Direct on
Amazon.com, making prescription-strength Avenova available for the
first time without a prescription.
“We are preparing for another direct-to-consumer launch later
this year for CelleRx, our product for aesthetic dermatology,” he
added. “This unique topical solution based on our pure hypochlorous
formulation, which is especially designed to gently clean and ease
discomfort following cosmetic procedures, targets a large global
market opportunity.”
The corporate presentation for these events will be available on
the Investors section of the Company's website.
About Avenova®
Avenova is an eye care product formulated with our proprietary,
stable and pure form of hypochlorous acid. Avenova is designed for
removal of the microorganisms and debris that contribute to
conditions such as meibomian gland dysfunction, dry eye and
blepharitis. Avenova is marketed to optometrists and
ophthalmologists throughout the U.S. by NovaBay’s direct salesforce
and available online direct-to-consumer through Amazon.com.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on commercializing and developing its non-antibiotic
anti-infective products to address the unmet therapeutic needs of
the global, topical anti-infective market with its two distinct
product categories: the NEUTROX® family of products and the
AGANOCIDE® compounds. The Neutrox family of products includes
AVENOVA® for the eye care market, NEUTROPHASE® for wound care
market, and CELLERX® for the aesthetic dermatology market. The
Aganocide compounds, still under development, have target
applications in the dermatology and urology markets.
Socialize and Stay informed on
NovaBay’s progress Like us on Facebook Follow
us on Twitter Connect with NovaBay on LinkedIn Visit
NovaBay’s Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com.
www.Avenova.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190903005151/en/
NovaBay Contact Justin Hall
President and Chief Executive Officer 510-899-8800
jhall@novabay.com
Investor
Contact LHA Investor Relations Jody Cain 310-691-7100
jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Sep 2023 to Sep 2024